Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Baseline characteristics of the overall population and by tertiles of intact fibroblast growth factor 23 (iFGF23). | Overall(n = 150) | iFGF23< 35.2 pg/mL(n = 50) | iFGF2335.2 to 50.9 pg/mL(n = 50) | iFGF23> 50.9 pg/mL(n = 50) | p value(trend): 25-hydroxyvitamin D3, ng/mL | 16.26 (9.40-24.49) | 15.19 (7.60 to 21.50) | 20.53 (13.63 to 25.97) | 15.83 (9.09 to 25.44) | 0.078
Source: Results table. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
All patients were on stable guideline-recommended HF therapy since at least 3 months.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
Study design awaiting verification · BMC Cardiovascular Disorders · 2023
Original publication title
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Fibroblast growth factor-23 (FGF23) has been associated to left ventricular (LV) hypertrophy and heart failure (HF) severity. We aimed to investigate the clinical correlates and prognostic value of intact FGF23 (iFGF23) in HF patients.
Source: BackgroundAbstract: What methods does the paper describe?
Patients with stable HF and left ventricular ejection fraction (LVEF) < 50% were prospectively enrolled, managed according to current recommendations and followed over time. iFGF23 was measured at baseline with a fully automated immuno-chemiluminescent assay.
Source: MethodsAbstract: Results
We enrolled 150 patients (82% males; median age 65 years). First, second, and third iFGF23 tertiles were < 35.2 pg/mL, 35.2 to 50.9 pg/mL, and > 50.9 pg/mL. LVEF decreased from the first iFGF23 tertile to the third tertile (p = 0.014). N-terminal pro-B-type natriuretic peptide (NT-proBNP) increased from the first to the third tertile (p = 0.001), while peak oxygen consumption decreased (p < 0.001). Thirty-five patients (23%) experienced the primary endpoint (all-cause death or HF hospitalization at 5 years), and 26 (17%) the secondary endpoint (all-cause death at 5 years).
On multivariable analysis, iFGF23 independently predicted the primary endpoint on top of age, gender and LVEF (HR 4.6 [95% CI 2.1 to 10.3], p < 0.001), age, gender and eGFR (HR 4.1 [95% CI 1.6 to 10.3], p = 0.003), as well as age, gender and NT-proBNP (HR 3.6 [95% CI 1.6 to 8.2], p = 0.002). iFGF23 even reclassified patient risk on top of all the 3 models, with NRI values of 0.65 (95% CI 0.30 to 1.01), 0.55 (95% CI 0.25 to 0.88), and 0.60 (95% CI 0.24 to 0.96), respectively (both p < 0.001).
Source: ResultsAbstract: Conclusions
Circulating iFGF23 is associated with disease severity and outcome in HF patients with reduced and mildly reduced ejection fraction.
Source: ConclusionsAuthors’ abstract
Background
Fibroblast growth factor-23 (FGF23) has been associated to left ventricular (LV) hypertrophy and heart failure (HF) severity. We aimed to investigate the clinical correlates and prognostic value of intact FGF23 (iFGF23) in HF patients.
Methods
Patients with stable HF and left ventricular ejection fraction (LVEF) < 50% were prospectively enrolled, managed according to current recommendations and followed over time. iFGF23 was measured at baseline with a fully automated immuno-chemiluminescent assay.
Results
We enrolled 150 patients (82% males; median age 65 years). First, second, and third iFGF23 tertiles were < 35.2 pg/mL, 35.2 to 50.9 pg/mL, and > 50.9 pg/mL. LVEF decreased from the first iFGF23 tertile to the third tertile (p = 0.014). N-terminal pro-B-type natriuretic peptide (NT-proBNP) increased from the first to the third tertile (p = 0.001), while peak oxygen consumption decreased (p < 0.001). Thirty-five patients (23%) experienced the primary endpoint (all-cause death or HF hospitalization at 5 years), and 26 (17%) the secondary endpoint (all-cause death at 5 years).
On multivariable analysis, iFGF23 independently predicted the primary endpoint on top of age, gender and LVEF (HR 4.6 [95% CI 2.1 to 10.3], p < 0.001), age, gender and eGFR (HR 4.1 [95% CI 1.6 to 10.3], p = 0.003), as well as age, gender and NT-proBNP (HR 3.6 [95% CI 1.6 to 8.2], p = 0.002). iFGF23 even reclassified patient risk on top of all the 3 models, with NRI values of 0.65 (95% CI 0.30 to 1.01), 0.55 (95% CI 0.25 to 0.88), and 0.60 (95% CI 0.24 to 0.96), respectively (both p < 0.001).
Conclusions
Circulating iFGF23 is associated with disease severity and outcome in HF patients with reduced and mildly reduced ejection fraction.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12872-023-03441-2.
Publication and source details
Original title: Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
Giuseppe Vergaro; Annamaria Del Franco; Alberto Aimo; Francesco Gentile; Vincenzo Castiglione; Federica Saponaro; Silvia Masotti; Concetta Prontera; Niccolò Fusari; Michele Emdin; Claudio Passino
BMC Cardiovascular Disorders · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T16:36:32.571591+00:00
DOI: 10.1186/s12872-023-03441-2 · PMC10474676